布地奈德或丙酸倍氯米松结合硫酸沙丁胺醇治疗肺炎支原体肺炎患儿效果对比  

Comparison of Efficacy Between Budesonide or Beclomethasone Propionate Combined with Salbutamol Sulfate in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children

作　　者：曲春霞[1] Qu Chunxia(Department of Pediatric Medicine,Tanghe County People’s Hospital,Nanyang,Henan,473400,China)

机构地区：[1]河南省唐河县人民医院小儿内科,河南唐河473400

出　　处：《黑龙江医学》2025年第4期472-475,共4页Heilongjiang Medical Journal

摘　　要：目的:探讨布地奈德或丙酸倍氯米松结合硫酸沙丁胺醇治疗肺炎支原体肺炎(MPP)患儿效果对比。方法:选取2022年3月-2023年3月河南省唐河县人民医院收治的100例MPP患儿作为研究对象,按随机数表法分为两组,每组各50例。对照组患儿用硫酸沙丁胺醇结合丙酸倍氯米松治疗,观察组患儿用硫酸沙丁胺醇结合布地奈德治疗,均治疗7 d。比较两组患儿临床疗效、症状消失时间、免疫功能、炎性因子水平、肺功能及不良反应。结果:观察组患儿临床疗效高于对照组,差异有统计学意义(χ^(2)=4.000,P<0.05)。治疗后,观察组患儿咳嗽、退热、气喘缓解、双肺喘鸣音等症状消失及住院时间短于对照组;免疫球蛋白G (IgG)、免疫球蛋白M (IgM)、免疫球蛋白A (IgA)指标高于对照组;肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白介素细胞-4 (IL-4)、白介素细胞-8 (IL-8)水平低于对照组;用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、一秒率(FEV1/FVC)指标高于对照组;最大呼气峰流速(PEF)低于对照组,差异均有统计学意义(t=15.532、 10.488、 17.132、 12.217、 5.162、 9.487、 12.900、 7.555、 10.993、 14.389、 14.451、 15.525、 8.363、0.180、10.713、2.082,P<0.05);两组患儿不良反应比较,差异无统计学意义(χ^(2)=0.444,P>0.05)。结论:硫酸沙丁胺醇结合布地奈德治疗效果优于丙酸倍氯米松结合硫酸沙丁胺醇治疗,可有效提高MPP患儿临床疗效,缓解其临床症状、缩短住院时间、增强免疫力、改善肺功能、降低机体炎症因子水平,安全可靠。Objective:To compare the efficacy of budesonide or beclomethasone propionate combined with salbutamol sulfate in the treatment of Mycoplasma pneumoniae pneumonia(MPP)in children.Methods:100 children with MPP were selected and admitted to Tanghe County People’s Hospital from March 2022 to March 2023.They were divided into 2 groups,with 50 cases in each group according to random number table method.The control group was treated with salbutamol sulfate combined with beclomethasone propionate,and the observation group was treated with salbutamol sulfate combined with budesonide for 7 days.The clinical efficacy,symptom disappearance time,immune function,inflammatory factor levels,lung function,and adverse reactions between the two groups of children were companed.Results:The clinical efficacy of the observation group was higher than that of the control group,with statistically significant difference(x^(2)=4.000,P<0.05).After treatment,the symptom disappearance of cough,fever,asthma and wheezing in both lungs,and the length of hospitalization in the observation group were shorter than that in the control group.The indexes of immunoglobulin G(IgG),immunoglobulin M(IgM)and immunoglobulin A(IgA)were higher than those of control group.The levels of tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),interleukin-4(IL-4)and interleukin-8(IL-8)were lower than those of control group.Forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and one-second rate(FEV1/FVC)were higher than those in the control group.The maximum expiratory peak velocity(PEF)was lower than that of control group,with statistically significant difference(t=15.532,10.488,17.132,12.217,5.162,9.487,12.900,7.555,10.993,14.389,14.451,15.525,8.363,0.180,10.713,2.082;P<0.05).There was no significant difference in adverse reactions between the two groups(χ^(2)=0.444,P>0.05).Conclusion:The treatment effect of salbutamol sulfate combined with budesonide is better than that of beclomethasone propionate combined with salbutamol sulfate.I

关 键 词：肺炎支原体肺炎 布地奈德 硫酸沙丁胺醇 丙酸倍氯米松 

分 类 号：R375.2[医药卫生—病原生物学]